Novo Nordisk SG&A Expenses 2010-2024 | NVO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Novo Nordisk annual sg&a expenses for 2023 were $8.944B, a 24.62% increase from 2022.
Novo Nordisk annual sg&a expenses for 2022 were $7.177B, a 9.87% increase from 2021.
Novo Nordisk annual sg&a expenses for 2021 were $6.532B, a 15.6% increase from 2020.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Novo Nordisk annual sg&a expenses for 2023 were $8.944B, a 24.62% increase from 2022.
Novo Nordisk annual sg&a expenses for 2022 were $7.177B, a 9.87% increase from 2021.
Novo Nordisk annual sg&a expenses for 2021 were $6.532B, a 15.6% increase from 2020.